| Bioactivity | FXIa-IN-15 (Compound (S)-10h) is an inhibitor for Factor XIa (FXIa) and plasma kallikrein (PKa) with an IC50 of 0.38 nM and 59.2 nM. FXIa-IN-15 exhibits anticoagulant efficacy, that extends 50% activated partial thromboplastin time (aPTT) with EC1.5X of 0.55 μM[1]. |
| CAS | 3053222-76-4 |
| Formula | C32H23ClF3N7O4 |
| Molar Mass | 662.02 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Dai L, et al., Discovery of potent and selective factor XIa inhibitors incorporating triazole-based benzoic acid as novel P2' fragments: Molecular dynamics simulations and anticoagulant activity. Eur J Med Chem. 2025 Jan 15;282:117067. |
FXIa-IN-15
CAS: 3053222-76-4 F: C32H23ClF3N7O4 W: 662.02
FXIa-IN-15 (Compound (S)-10h) is an inhibitor for Factor XIa (FXIa) and plasma kallikrein (PKa) with an IC50 of 0.38 nM
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.